<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Treatment with granulocyte colony-stimulating factor (G-CSF) plus erythropoietin may synergistically improve <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> levels and reduce bone marrow <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in patients with <z:hpo ids='HP_0004828'>refractory anemia with ringed sideroblasts</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Fas-induced caspase activity is increased in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> bone marrow cells </plain></SENT>
<SENT sid="2" pm="."><plain>We showed that G-CSF significantly reduced Fas-mediated caspase-8 and caspase-3-like activity and the degree of nuclear apoptotic changes in bone marrow from nine <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>A decrease in <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane potential and an increase in intracellular reactive oxygen species occurred in Fas-treated cells, but became significant only 24 h after changes in caspase activity and decrease in proliferation </plain></SENT>
<SENT sid="4" pm="."><plain>G-CSF also reduced the magnitude of these late apoptotic changes </plain></SENT>
<SENT sid="5" pm="."><plain>In CD34-selected <z:mpath ids='MPATH_458'>normal</z:mpath> cells, G-CSF induced myeloid colony growth, and an overall small decrease in the number of erythroid colonies </plain></SENT>
<SENT sid="6" pm="."><plain>By contrast, G-CSF induced a 33-263% increase of erythroid colony formation in CD34+ cells from four of five <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> patients with severely reduced erythroid growth, while the <z:mpath ids='MPATH_458'>normal</z:mpath> or slightly reduced erythroid growth of three other patients was not influenced by G-CSF </plain></SENT>
<SENT sid="7" pm="."><plain>This study suggests that G-CSF may reduce the pathologically increased caspase activity and concomitant apoptotic changes, and promote erythroid growth and differentiation of stem cells from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>Our data support the clinical benefit of G-CSF in this subgroup of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
</text></document>